| Autor: |
Huang J; School of Pharmaceutical Science and Technology, Dalian University of Technology, Dalian, 116024 China., Liu J; School of Pharmaceutical Science and Technology, Dalian University of Technology, Dalian, 116024 China., Chen-Xiao K; Harbor-University of California Los Angeles Research and Education Institute, UCLA School of Medicine, Torrance, CA 90502 USA., Zhang X; Harbor-University of California Los Angeles Research and Education Institute, UCLA School of Medicine, Torrance, CA 90502 USA., Lee WN; Harbor-University of California Los Angeles Research and Education Institute, UCLA School of Medicine, Torrance, CA 90502 USA., Go VL; Harbor-University of California Los Angeles Research and Education Institute, UCLA School of Medicine, Torrance, CA 90502 USA., Xiao GG; School of Pharmaceutical Science and Technology, Dalian University of Technology, Dalian, 116024 China ; Harbor-University of California Los Angeles Research and Education Institute, UCLA School of Medicine, Torrance, CA 90502 USA ; Genomics and Functional Proteomics Laboratories, Creighton University Medical Center, Omaha, NE 68131 USA. |
| Abstrakt: |
Pancreatic cancer is characterized as a disease with low survival and high mortality because of no effective diagnostic and therapeutic strategies available in clinic. Conventional clinical diagnostic methods including serum markers and radiological imaging (CT, MRI, EUS, etc.) often fail to detect precancerous or early stage lesions. Development of effective biomarkers is unmet for reduction of mortality of pancreatic cancer. MicroRNAs (miRNAs) are a group of small non-protein-coding RNAs playing roles in regulation of cell physiology including tumorigenesis, apoptotic escape, proliferation, invasion, epithelial-mesenchymal transition (EMT), metastasis and chemoresistance. Various altered signaling pathways involving in molecular pathogenesis of pancreatic cancer are mediated by miRNAs as a role of either oncogenes or tumor suppressors. Among biomarkers developed including protein, metabolites, DNA, RNA, epigenetic mutation, miRNAs are superior because of its unique chemical property. Recent study suggests that miRNAs may be promising biomarkers used for early detection of pancreatic cancer. This review will update the progression made in early detection of pancreatic cancer. |
Full text from SpringerLink